Exagen Q1 revenue up 28% to $14.4M; raises FY2024 guidance

EXAGEN INC.

2024-Q1 EPS reported -$0.19 revenue$14,415,000

Revenue $14.4M, +28.4% YoY; gross margin 59.6% vs 47.2% a year ago.
Net loss $3.4M, a 56.3% improvement; adjusted EBITDA -$2.0M, a 67.7% improvement.
AVISE CTD trailing 12-month ASP $377, up 35.1% versus prior year.
Company raises full-year 2024 revenue and adjusted EBITDA guidance on strong momentum.
Cash and equivalents $27.3M; accounts receivable $10.9M; cash runway into 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

EXAGEN INC. reported the quarter ended March 31, 2024 results: revenue $14.4 million, net income $3.4 million. Guidance raised.

Period: the quarter ended March 31, 2024
Revenue: $14.4 million
Net income: $3.4 million
Guidance: raised
Result: reported results

Exact text from the filing

leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2024. First Quarter Highlights: • Recognized total revenue of $14.4 million in the first quarter of 2024, a 28.4% increase over the first quarter of 2023. • Delivered gross margin of 59.6% in the first quarter of 2024, compared to a gross margin of 47.2%

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

EXAGEN INC. filing history →

Source: SEC EDGAR

accession 0001274737-24-000045

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.